After infection, herpes lurks in nerve cells, ready to strike—New research reveals what enables the virus to do so

March 15, 2018, Harvard Medical School
Herpes simplex virus. Credit: CDC

Once herpes simplex infects a person, the virus goes into hiding inside nerve cells, hibernating there for life, periodically waking up from its sleep to reignite infection, causing cold sores or genital lesions to recur.

How exactly does the virus—harbored by more than two-thirds of the population worldwide—manage to establish those silent infections only to come out of hiding every so often?

It's a question that has vexed virologists for decades. Now research from Harvard Medical School, published Feb. 6 in the journal mBio, shows that the virus uses a host protein called CTCF, or cellular CCCTC-binding factor, to do just that.

In a series of experiments conducted in mice, the researchers revealed that CTCF helps herpes simplex regulate its own sleep-wake cycle, enabling the virus to establish latent infections in the body's sensory neurons where it remains dormant until reactivated. Preventing that latency-regulating protein from latching onto, or binding to, the virus's DNA, weakened the virus's ability to come out of hiding, the research showed.

Herpes simplex virus's ability to go in and out of hiding is a key survival strategy that ensures its propagation from one host to the next. Such symptom-free latency allows the virus to remain out of the reach of the immune system most of the time, while its periodic reactivation ensures that it can continue to spread from one person to the next.

"Our findings shed light on one of the more confounding behaviors of the herpes simplex virus—its ability to transition between silent and active , a state of so-called poised latency, which allows it to be quiet yet remain on standby," said study senior investigator David Knipe, the Higgins Professor of Microbiology and Molecular Genetics and interim co-chair of the Department of Microbiology and Immunobiology.

Previous research by Knipe and colleagues has revealed that the sleep-wake cycle of the virus is regulated by a see-saw type of interaction between two sets of genes. On one hand, so-called latency-associated transcript genes, or LAT genes, turn off the transcription of viral RNA, inducing the virus to go into hibernation, or latency. On the other hand, a protein made by a gene called ICP0 promotes the activity of genes that stimulate and causes active infection. Past studies have shown that at times the LAT gene and the ICP0 gene act in opposition to each other, inducing the virus to alternate between dormant and active states, but at times they act in concert to promote either latency or reactivation. The genes are also neighbors, occupying overlapping sites on the viral genome.

Building on these earlier findings, the new study reveals that this balancing act is enabled by the CTCF protein when it binds to the viral DNA. Present during latent or dormant infections, CTCF is lost during active, symptomatic infections.

To test their hypothesis that CTCF is a key regulator of the viral sleep-wake cycle, the researchers homed in on so-called binding sites, spots on the virus's DNA where the CTCF protein latches on to turn on infection-silencing LAT genes while keeping a lid on the that awaken the virus.

The researchers created an altered version of the virus that lacked two of the CTCF binding sites. The absence of the binding sites made no difference in early-stage or acute infections, the researchers observed. In a lab dish, human cells infected with the mutant form of the virus showed similar levels of viral replication with cells infected with the intact virus. The same pattern emerged when the virus was introduced in mice. Animals infected with the normal and mutant forms of the virus had similar viral loads during the early stages of infection.

When researchers examined the virus's behavior in cells obtained from clusters of known as trigeminal ganglia, they observed the same pattern. During latent infection, viral levels were similar in the nerve cells of mice infected with both forms of the virus. However, when the virus got reactivated, a striking difference emerged. Nearly 80 percent of nerve ganglia cells obtained from mice infected with regular and grown into a lab dish churned out viral copies. By contrast only 53 percent of nerve cells from mice infected with the mutant form of the virus lacking CTCF binding sites produced detectable virus. The had significantly weakened reactivation capacity, the researchers concluded.

Taken together, the experiments show that deleting the CTCF binding sites weakened the 's ability to wake up from its dormant state—evidence that the CTCF protein is a key regulator of in herpes simplex infections.

Explore further: Scientists advance understanding of herpesvirus infection

Related Stories

Scientists advance understanding of herpesvirus infection

April 12, 2017
Herpes simplex virus (HSV) infections last a lifetime. Once a person has been infected, the virus can remain dormant (latent) for years before periodically reactivating to cause recurrent disease. This poorly understood cycle ...

Herpes virus mutant points towards new vaccine strategy

December 19, 2017
A Northwestern Medicine study published in PLOS Pathogens describes a newly-designed mutant herpes virus called R2 that provides a strategy for the development of novel herpes virus vaccines.

Herpesvirus study in mice leads to discovery of potential broad-spectrum antiviral

August 15, 2017
After herpesviruses infect a cell, their genomes are assembled into specialized protein structures called nucelosomes. Many cellular enzyme complexes can modulate these structures to either promote or inhibit the progression ...

Preclinical evaluation of a vaccine against herpes viruses

August 4, 2016
Oral and genital herpes are caused by the herpes simplex virus type 1 (HSV-1) and the herpes simplex virus type 2 (HSV-2), which both cause lifelong infection. HSV-2 infection is associated with increased risk for HIV infection. ...

Recommended for you

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.